Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Protagonist Therapeutics

05/08/2026 22:22

Protagonist Therapeutics, Inc. PTGX.OQ reported quarterly adjusted earnings of $2.29​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -55 cents.  The mean expectation of thirteen analysts for the quarter was for earnings of $2.08 per share. Wall Street expected results to range from 90 cents to $2.79 per share.
Revenue rose 3,749.2% to $213.48 million from a year ago; analysts expected $203.76 million. 
Protagonist Therapeutics, Inc.'s reported EPS for the quarter was $2.29​.
The company reported quarterly net income of $162.85 million.
Protagonist Therapeutics, Inc. shares had risen by 10.8% this quarter and gained 55.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.3% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Protagonist Therapeutics, Inc. is $130.00, about 4.5% below its last closing price of $135.81
This summary was machine generated from LSEG data August 5 at 09:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
2.08
2.29
Beat
Mar. 31 2026 
-0.53
0.05
Beat
Dec. 31 2025 
-0.49
-0.69
Missed
Sep. 30 2025 
-0.64
-0.62
Beat